General guidelines for the evaluation of new anti-infective drugs for the treatment of skin, skin-structure, bone, and joint infections: Evaluation of new anti-infective drugs for the treatment of selected infections of the skin and skin structure

Gary B. Calandra, Carl Norden, John D. Nelson, Jon T. Mader

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

No method for classifying infections of the skin and skin structure is uniformly accepted. Therefore, each protocol for the evaluation of new anti-infective drugs must include definitions of the skin and skin-structure infections to be treated. Clinical findings may suggest the etiology. Cultures should be performed by the best available technique. Because the yield of pathogens from sites of skin and skin-structure infection is often low, monitoring of the clinical response to therapy is paramount. Randomized, double-blind, active-control comparative studies are needed, and maintenance of blinding is recommended, even with a change in the route of administration of the study and/or control drugs. The period of follow-up should be defined for each type of infection.

Original languageEnglish (US)
Pages (from-to)S148-S154
JournalClinical Infectious Diseases
Volume15
DOIs
StatePublished - Jan 1 1992

Fingerprint

Joints
Guidelines
Bone and Bones
Skin
Infection
Pharmaceutical Preparations
Therapeutics
Drug Administration Routes
Drug and Narcotic Control
Maintenance

ASJC Scopus subject areas

  • Infectious Diseases
  • Microbiology (medical)

Cite this

@article{c4cbe8f99d1f42fb9aa4a5de3e25f9c5,
title = "General guidelines for the evaluation of new anti-infective drugs for the treatment of skin, skin-structure, bone, and joint infections: Evaluation of new anti-infective drugs for the treatment of selected infections of the skin and skin structure",
abstract = "No method for classifying infections of the skin and skin structure is uniformly accepted. Therefore, each protocol for the evaluation of new anti-infective drugs must include definitions of the skin and skin-structure infections to be treated. Clinical findings may suggest the etiology. Cultures should be performed by the best available technique. Because the yield of pathogens from sites of skin and skin-structure infection is often low, monitoring of the clinical response to therapy is paramount. Randomized, double-blind, active-control comparative studies are needed, and maintenance of blinding is recommended, even with a change in the route of administration of the study and/or control drugs. The period of follow-up should be defined for each type of infection.",
author = "Calandra, {Gary B.} and Carl Norden and Nelson, {John D.} and Mader, {Jon T.}",
year = "1992",
month = "1",
day = "1",
doi = "10.1093/clind/15.Supplement_1.S148",
language = "English (US)",
volume = "15",
pages = "S148--S154",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",

}

TY - JOUR

T1 - General guidelines for the evaluation of new anti-infective drugs for the treatment of skin, skin-structure, bone, and joint infections

T2 - Evaluation of new anti-infective drugs for the treatment of selected infections of the skin and skin structure

AU - Calandra, Gary B.

AU - Norden, Carl

AU - Nelson, John D.

AU - Mader, Jon T.

PY - 1992/1/1

Y1 - 1992/1/1

N2 - No method for classifying infections of the skin and skin structure is uniformly accepted. Therefore, each protocol for the evaluation of new anti-infective drugs must include definitions of the skin and skin-structure infections to be treated. Clinical findings may suggest the etiology. Cultures should be performed by the best available technique. Because the yield of pathogens from sites of skin and skin-structure infection is often low, monitoring of the clinical response to therapy is paramount. Randomized, double-blind, active-control comparative studies are needed, and maintenance of blinding is recommended, even with a change in the route of administration of the study and/or control drugs. The period of follow-up should be defined for each type of infection.

AB - No method for classifying infections of the skin and skin structure is uniformly accepted. Therefore, each protocol for the evaluation of new anti-infective drugs must include definitions of the skin and skin-structure infections to be treated. Clinical findings may suggest the etiology. Cultures should be performed by the best available technique. Because the yield of pathogens from sites of skin and skin-structure infection is often low, monitoring of the clinical response to therapy is paramount. Randomized, double-blind, active-control comparative studies are needed, and maintenance of blinding is recommended, even with a change in the route of administration of the study and/or control drugs. The period of follow-up should be defined for each type of infection.

UR - http://www.scopus.com/inward/record.url?scp=84963017625&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963017625&partnerID=8YFLogxK

U2 - 10.1093/clind/15.Supplement_1.S148

DO - 10.1093/clind/15.Supplement_1.S148

M3 - Article

C2 - 1477222

AN - SCOPUS:84963017625

VL - 15

SP - S148-S154

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

ER -